PR Newswire BiotechOriginal article
Brii Bio Announces Topline End-of-Treatment Data from Phase 2b ENRICH and ENHANCE Studies for the Treatment of Chronic Hepatitis B
Phase 2MixedBRII-179Neutral
AI Analysis
Summary
Brii Bio announced end-of-treatment data from Phase 2b ENRICH and ENHANCE studies of BRII-179 for chronic hepatitis B, with ENRICH showing higher HBsAg loss rates while ENHANCE failed to demonstrate improved HBsAg loss compared to comparator.
Clinical Trial Data
Phase
2b
Primary Endpoint
Not Met
Outcome Details
ENRICH demonstrated higher HBsAg loss rates consistent with ENSURE Cohort 4; ENHANCE did not demonstrate improved HBsAg loss rates compared to control
Importance:6/10
Sentiment:
0.20
Chronic Hepatitis BHBsAg lossFunctional cureImmune responsePhase 2b
Related Companies
Read the original article
Published by PR Newswire Biotech on July 3, 2026 12:00 AM